A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

• Status: Completed
• Trial end date: 2019-08-28
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Reata Pharmaceuticals, Inc.
• Collaborator: Covance
• Treatments: Digoxin; Gemfibrozil; Hydroxyitraconazole; Itraconazole; Metformin; Midazolam; Repaglinide; Rosuvastatin Calcium; Verapamil

Criteria

Inclusion Criteria:

Subjects must satisfy all of the following criteria at the Screening Visit unless otherwise stated:

• Males or females, of any race, between 18 and 55 years of age, inclusive.

• Body mass index between 18.0 and 32.0 kg/m2, inclusive, and a total body weight >50 kg.

• In good health.

• Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.

• Able to comprehend and willing to sign an ICF and to abide by the study restrictions.

Exclusion Criteria:

Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit, unless otherwise stated:

• Significant history or clinical manifestation of any major system disorder, as determined by the investigator (or designee).

• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).

• History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (cholecystectomy will not be allowed; uncomplicated appendectomy and hernia repair will be allowed).

• History of alcoholism or drug/chemical abuse within 2 years prior to Check in (Day 1).

• Abnormal laboratory values considered clinically significant by the investigator

• Clinically significant abnormal 12 lead ECGs

• Personal history of unexplained syncopal events, or family history of long QT syndrome or sudden unexplained death in a young person.

• Pulse rate <50 bpm or systolic blood pressure <110 mmHg.

• Alcohol consumption of >21 units per week for males and >14 units for females.

• Positive urine drug screen or positive alcohol breath test result or positive urine drug screen.

• Positive hepatitis panel and/or positive human immunodeficiency virus test. Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 30 days prior to dosing or 5 half lives (if known), whichever is longer, prior to dosing.

• Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).

• Have previously completed or withdrawn from this study or any other study investigating omaveloxolone, and have previously received the investigational product.

• Subjects who, in the opinion of the investigator (or designee), should not participate in this study.